Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.

Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, Henne K, Leyns CE, Gallardo G, Ulrich JD, Sullivan PM, Lerner EP, Hudry E, Sweeney ZK, Dennis MS, Hyman BT, Watts RJ, Holtzman DM.

J Clin Invest. 2018 May 1;128(5):2144-2155. doi: 10.1172/JCI96429. Epub 2018 Mar 30.

2.
3.

APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.

Kunzler J, Youmans KL, Yu C, Ladu MJ, Tai LM.

Neurosci Lett. 2014 Feb 7;560:131-6. doi: 10.1016/j.neulet.2013.12.032. Epub 2013 Dec 22.

4.

Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis.

Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM.

J Neurosci. 2011 Dec 7;31(49):18007-12. doi: 10.1523/JNEUROSCI.3773-11.2011.

5.
6.

Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.

Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM.

J Neurosci. 2014 May 21;34(21):7281-92. doi: 10.1523/JNEUROSCI.0646-14.2014.

7.

Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice.

Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y.

J Neurosci. 2012 Apr 4;32(14):4803-11. doi: 10.1523/JNEUROSCI.0033-12.2012.

8.

Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.

Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM.

J Neurosci. 2005 Mar 16;25(11):2803-10.

9.
10.

Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.

Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV.

Mol Neurodegener. 2018 Oct 19;13(1):57. doi: 10.1186/s13024-018-0286-0.

11.

Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.

Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM.

Acta Neuropathol Commun. 2015 Nov 10;3:70. doi: 10.1186/s40478-015-0250-y.

12.

Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.

Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, Holtzman DM, Sadowski MJ.

Acta Neuropathol Commun. 2014 Jun 28;2:75. doi: 10.1186/s40478-014-0075-0.

13.

APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.

Tachibana M, Holm ML, Liu CC, Shinohara M, Aikawa T, Oue H, Yamazaki Y, Martens YA, Murray ME, Sullivan PM, Weyer K, Glerup S, Dickson DW, Bu G, Kanekiyo T.

J Clin Invest. 2019 Mar 1;129(3):1272-1277. doi: 10.1172/JCI124853. Epub 2019 Feb 11.

14.

APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.

Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, Ladu MJ.

J Biol Chem. 2012 Dec 7;287(50):41774-86. doi: 10.1074/jbc.M112.407957. Epub 2012 Oct 11.

15.

Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, Cornwell LB, Miller CA, Vinters HV, Van Eldik LJ, Fardo DW, Estus S, Bu G, Gylys KH, Ladu MJ.

J Biol Chem. 2013 Feb 22;288(8):5914-26. doi: 10.1074/jbc.M112.442103. Epub 2013 Jan 4.

16.

ApoE4 Accelerates Early Seeding of Amyloid Pathology.

Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, Bu G.

Neuron. 2017 Dec 6;96(5):1024-1032.e3. doi: 10.1016/j.neuron.2017.11.013.

17.

The interaction of amyloid-beta with ApoE.

Carter DB.

Subcell Biochem. 2005;38:255-72. Review.

PMID:
15709483
18.

Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.

Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, Holtzman DM.

J Neurosci. 2002 Dec 1;22(23):10083-7.

19.

Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism.

Zhao L, Lin S, Bales KR, Gelfanova V, Koger D, Delong C, Hale J, Liu F, Hunter JM, Paul SM.

J Neurosci. 2009 Mar 18;29(11):3603-12. doi: 10.1523/JNEUROSCI.5302-08.2009.

20.

Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.

Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R.

J Neurosci. 2012 Sep 19;32(38):13125-36.

Supplemental Content

Support Center